Axsome Unveils New AUVELITY Data at ASCP 2026, Highlighting Anxiolytic Effects in Depression

Event summary

  • Axsome presented three posters on AUVELITY (dextromethorphan-bupropion) at ASCP 2026, focusing on major depressive disorder with anxious distress.
  • Posters included real-world outcomes data and anxiolytic effects analysis, led by Jeffrey R. Strawn, MD, and Joel L. Young, MD.
  • Additional data on solriamfetol's neuropsychological outcomes in obstructive sleep apnea was also presented.
  • Presentations occurred May 27–28, 2026, in Miami, FL.

The big picture

Axsome's ASCP 2026 presentations underscore its push to position AUVELITY as a differentiated treatment for MDD with anxious distress, a segment with significant unmet need. The focus on real-world data aligns with payers' growing emphasis on outcomes-based pricing. If successful, this strategy could bolster Axsome's market position against established antidepressants and emerging therapies targeting treatment-resistant depression.

What we're watching

Clinical Validation
Whether AUVELITY's anxiolytic effects data can differentiate it in the competitive MDD market.
Regulatory Pathway
The pace at which Axsome advances additional indications for solriamfetol.
Commercial Strategy
How Axsome leverages real-world outcomes data to expand payer coverage for AUVELITY.